



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Michael A. REEVE

Serial No. 07/855,036

Filed May 1, 1992

THE COMMISSIONER IS AUTHORIZED
TO CHARGE ANY DEFICIENCY IN THE
FEE FOR THIS PAPER TO DEPOSIT
ACCOUNT NO. 23-0975.

Group Art Unit 1815

Examiner T. Reardon

METHOD TO ISOLATE MACROMOLECULES:
USING MAGNETICALLY ATTRACTABLE
BEADS WHICH DO NOT SPECIFICALLY :
BIND THE MACROMOLECULES

INFORMATION DISCLOSURE STATEMENT

Honorable Commissioner of Patents and Trademarks,
Washington, D.C. 20231

Sir:

Pursuant to the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, Applicant requests consideration of (X) the references listed on the attached Form PTO-1449 and/or () the additional information identified below in paragraph 3. A legible copy of each reference listed on the Form PTO-1449 is enclosed, except a copy is not provided for each reference previously cited by or submitted to the Patent Office in prior parent application Serial No. .

1. This Information Disclosure Statement is submitted:

- a. () within 3 months of the filing date of the above-identified application, or () within 3 months of entry into National stage prosecution of an International application, or () before the mailing date of the first Office Action on the merits, and thus:

() no certification and/or fee is required.

- b. (X) after the events of above paragraph 1a and prior to the mailing date of a final Office Action or Notice of Allowance, and thus:

() the certification of paragraph 2 below is provided,
or
(X) a fee of \$200.00 is enclosed.

- c. () after the mailing date of a final Office Action or a Notice of Allowance and prior to payment of the issue fee, and thus:

() the certification of paragraph 2 below is provided,
and
() a Petition and fee of \$ are enclosed.

2. It is hereby certified

() that each item of information contained in this

Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Statement, or

- () that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the Statement.
- 3. () Consideration of the following additional information (including any co-pending or abandoned U.S. application, prior uses and/or sales, etc.) is requested:
- 4. () For each non-English language reference listed on the attached Form PTO-1449:
 - () reference is made to an English language translation submitted herewith, and/or
 - () reference is made to a foreign patent office search report (in the English language) submitted herewith, and/or
 - () reference is made to an English language translation of a foreign patent office search report submitted herewith, and/or
 - () reference is made to the concise explanation contained in the specification of the present application at page(s) , and/or
 - () reference is made to the concise explanation set forth below:
- 5. (X) Applicant also offers the following comments for the Examiner's consideration: Enclosed herewith are the references in the International Search Report from the PCT International application from which this case is derived, and copies of the cited references are enclosed. Please note that DE-A-686243 (Pfizer) is in fact a counterpart of U.S. 3,470,067 (Warren et al.). Also, enclosed is a copy of a paper by Munro et al. in Biotechnology Letters, Vol. 3, No. 6, p.297-302 (1981), entitled "Magnetic Seeding to Aid Recovery of Biological Precipitates". This is the article referred to in Chemical Abstracts (1981), Vol. 95, abstract 76474q.

Respectfully submitted,

Michael A. REEVE

By Matthew Jacob
Matthew Jacob
Registration No. 25,154
Attorney for Applicant

MJ/pjm
Washington, D.C.
Telephone (202) 371-8850
October 20, 1993